Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PD1/PDL1/CTLA4 inhibitors

Phase 3Small molecule

SSecond Affiliated Hospital of Guangzhou Medical University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head/neck CancersRecruiting

Head/neck CancersPhase 3

Recruiting

Timeline

Expected Milestones

Q1 2035

Phase 2/3Recruiting

Head/neck Cancers

NCT03952065

Clinical

Trials by Indication[1]

Head/Neck Cancers1 trial

IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2/3·NCT03952065·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PD1/PDL1/CTLA4 inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD1/PDL1/CTLA4 inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD1/PDL1/CTLA4 inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital of Guangzhou Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSecond Affiliated Hospital of Guangzhou Medical University

Related News